.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Union Health Minister JP Nadda and French President Emmanuel Macron recently inaugurated the Indo-French Centre for AI in Health (IF-CAIH) at AIIMS Delhi. This landmark move strengthens bilateral cooperation in AI in healthcare and emerging medical technologies. Therefore, the new centre aims to bridge the gap between clinical research and technological innovation. Additionally, the IF-CAIH builds on existing partnerships in digital health, human resources, and antimicrobial resistance.
President Macron emphasized the critical need for building sovereign computing capacity during the launch event. Furthermore, he noted that trusted AI systems must serve humanity while protecting children and cultural diversity. Consequently, both nations committed to developing domestic talent to avoid overdependence on foreign technologies. Specifically, the centre results from an MoU between AIIMS, Sorbonne University, and the Paris Brain Institute. Moreover, researchers from IIT Delhi will contribute to these interdisciplinary healthcare solutions.
The launch coincided with the RUSH 2026 forum, which brought together global scientific leaders in New Delhi. Specifically, one high-level session focused on the role of AI in brain health and global medical challenges. Overall, this partnership reflects a shared vision for ethical and inclusive innovation in medicine. Ultimately, the centre provides a robust platform for young innovators to explore clinical cross-border collaboration.
Q1: What is the primary objective of the Indo-French Centre for AI in Health?
The IF-CAIH is designed to advance AI-driven research, medical education, and clinical innovation. It addresses complex healthcare challenges through interdisciplinary collaboration between India and France.
Q2: Which institutions are collaborating on this AI healthcare project?
The initiative involves a joint partnership between AIIMS Delhi, Sorbonne University, and the Paris Brain Institute. Additionally, the Indian Institute of Technology (IIT) Delhi and other French institutions provide academic support.
Q3: How does the centre address ethical concerns in artificial intelligence?
The partnership focuses on building sovereign, trusted AI systems. It emphasizes algorithmic transparency to address bias, protect data privacy, and ensure linguistic and cultural diversity in health solutions.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
India and France launch the IF-CAIH at AIIMS Delhi to advance AI-driven medical research, clinical innovation, and brain health through bilateral cooperatio...
8 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
